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Despite significant progress in recent decades, tuberculosis continues to be a major 
cause of mortality in many parts of the world, and in some areas, even in high-income 
countries including the UK, it is on the rise once more. This resurgence is caused 
by two major challenges: people living with HIV, which greatly increases the risk of 
developing active TB disease, and the emergence of multi drug-resistant forms of TB 
that are extremely difficult to treat. 
Our School has for many years been at the forefront of tuberculosis research, diagnosis 
and treatment, working in collaboration with government agencies, universities and civil 
society partners across more than 70 projects in around 40 countries worldwide. 
In recent years, the TB Centre at the School has become established as a collaborative 
hub to further develop and co-ordinate this work. Thanks to the leadership of David 
Moore, and now Helen Fletcher, the Centre is growing to encompass all aspects of 
research from laboratory science in host and pathogen biology, deciphering the genetic 
code of drug resistant strains, to implementing new control strategies. 
This report highlights some of the projects, partnerships and areas in which the Centre 
is engaged. There is much to do, and as always the biggest challenge is to persuade 
governments and funders to work together and act strategically to build effective health 
systems and services. TB has throughout history been closely linked with poverty, and 
its control will come through sustained public health and socio-economic interventions 
that improve people’s quality of life.
I hope you will be inspired by what you read here to support the work of the TB Centre 
and join us in the common goal to understand, control, and ultimately eliminate this 
disease.
Baron Peter Piot Director and 
Professor of Global Health 
London School of Hygiene & 
Tropical Medicine
About the TB CentreForeword: working to tackle the intractable  
challenges of tuberculosis
TB kills more people worldwide than any other disease. In 2014, 
9.6 million people contracted TB and 1.5 million died from the 
disease. However, the number of people with a new diagnosis 
of TB has fallen by an average of 1.5% per year since 2000, 
and ending the disease by 2030 is among the health targets 
of the newly adopted Sustainable Development Goals. This is a 
daunting task, but if researchers, governments, NGOs, industry 
and funders respond now, working together we can achieve it.
The TB Centre at the London School of Hygiene & Tropical 
Medicine brings together more than 120 laboratory scientists, 
clinicians, epidemiologists, statisticians, public health specialists 
and policy-makers. Our shared purpose is to reduce the global 
burden of TB, through high quality research, education and 
knowledge translation.
Innovation
Through consultancy work, research meetings, seminars and 
journal clubs, we disseminate our work and generate new ideas. 
Members of the TB Centre are global leaders in areas including:
 clinical trial design
 epidemiology
 tracing of TB transmission using molecular tools
 host-pathogen interactions
 development and implementation of new diagnostics
 mathematical modelling
 health economics 
 health systems research
Collaboration
We work in more than 20 countries with high prevalence of TB 
across Asia, Africa and Latin America, and our researchers are 
strongly integrated with local academic institutions, governments 
and international organisations. 
Investing in the future
We are committed to training the next generations of TB 
researchers, and have an active student community within the TB 
Centre. Our collective goal is to generate new knowledge, and to 
transfer the highest quality research into policy and practice, and 
ultimately real-world impact. We invite you to join us.
Helen Fletcher, Director, TB Centre 
Katherine Fielding, Deputy Director, TB Centre
http://tb.lshtm.ac.uk
Twitter: @LSHTM_TB
This publication was collated and edited by Steve Smith, Helen Fletcher, David Moore and Patrick Wilson, November 2015.
Staff collecting TB data electronically, 
courtesy of ZAMSTAR (see page 6)
Staff at TB Centre retreat in Canterbury, November 2015, by Kristian Godfrey
Helen Fletcher Katherine Fielding
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Clinical trials: towards effective diagnosis  
and treatment 
Progress towards rapid and reliable diagnosis followed by 
effective drug treatment is vital in the effort to control 
tuberculosis. TB Centre investigators have been awarded 
funding for a number of major clinical trials which aim to effect 
this progress.
The current vaccine against tuberculosis, Bacille Calmette Guerin 
(BCG) is nearly a century old and does not provide effective 
protection against TB, especially in high incidence settings where 
it is most needed. To eventually eliminate TB, we need a new, 
highly efficacious vaccine. The TB Vaccine Initiative consortium 
(TBVAC2020) has been granted 24.6 million euros from the 
European Horizon 2020 programme and other government 
sources to advance new TB vaccine candidates from discovery 
to clinical development.  Three TB Centre principal investigators, 
Hazel Dockrell, Gregory Bancroft and Helen Fletcher, are leading 
on three separate projects as part of a consortium of 40 
research institutes, pioneering innovative approaches to vaccine 
development. 
Discovery and development of TB 
biomarkers of protection 
The Biomarkers of Protection work package of TBVAC2020 aims 
to optimise the measurement of candidate biomarkers and 
develop methods such as the Mycobacterial Growth Inhibition 
assay, which indicate the level of immunity a person has against 
TB. Host immune responses will be correlated with TB disease 
risk and the effect of helminth worm infections on mycobacterial 
growth inhibition will be analysed.
TB Centre members: Helen Fletcher, Andrea Zelmer, Hazel 
Dockrell, Steven Smith, Mateusz Hasso Agopsowicz, Shaheda 
Anwar
Standardised pre-clinical models for 
candidate TB vaccine evaluation 
This component of the TBVAC2020 research programme at 
the School will provide standardised head-to-head testing of 
candidate TB vaccines. Testing for both safety and efficacy will 
be performed using immune deficient mice.
TB Centre members: Gregory Bancroft, Felipe Cia
Preclinical Model 
Development
People are often affected by 
conditions that increase their 
risk of developing TB. These 
conditions include HIV, obesity 
and diabetes. New animal 
models will be developed to 
better reflect these human 
conditions that are associated 
with increased TB disease risk. 
This will improve our chances of 
identifying vaccines to protect 
vulnerable populations. 
TB Centre members: Helen 
Fletcher, Andrea Zelmer
Rapid urine-based screening for TB 
to reduce AIDS-related mortality in 
hospitalised patients in Africa
Post-mortem studies show that TB is the cause of between 
one-third and two-thirds of adult HIV/AIDS-related deaths 
recorded in health facilities in sub-Saharan Africa. However, 
around one half of these TB cases are undiagnosed at 
the time of death, highlighting the urgent need for new 
diagnostic approaches. Background studies conducted in 
Cape Town by Stephen Lawn show that a large majority of 
TB cases can be rapidly diagnosed from a urine sample 
within the first 24 hours of acute hospital admission, 
using a combination of two techniques: Determine TB-
LAM lateral-flow urine test and Xpert MTB/RIF testing of 
concentrated urine.
The three-year Screening for Tuberculosis to Reduce 
AIDS-Related Mortality in Hospitalized Patients in Africa 
(STAMP) study, started in 2015, is an individually-
randomised controlled trial that will assess the clinical 
outcomes of standard sputum-based testing with Xpert 
MTB/RIF plus additional urine-based screening, compared 
with the standard screening alone. Funded by a UK 
Medical Research Council, Department for International 
Development and Wellcome Trust Global Clinical Trials 
Scheme grant award of £2.1 million over three years, the 
trial is underway in both Malawi and KwaZulu Natal, South 
Africa.
Principal Investigator: Stephen D. Lawn; TB 
Centre co-investigators: Liz Corbett, Katherine 
Fielding, Clare Flach
The XTEND study: evaluating Xpert MTB/
RIF as a first line TB test in South Africa
The XTEND study evaluated the impact of the new diagnostic 
test Xpert MTB/RIF in the context of its national roll-out in South 
Africa. It was a cluster-randomised trial, in which study clinics 
were randomised to early implementation of Xpert MTB/RIF as 
their first-line TB diagnostic test, while control clinics continued 
to use smear microscopy, which is the standard test. The study 
included over 4,600 people giving sputum to be tested for TB. 
The results, recently published in Lancet Global Health, showed 
that mortality at six months was not lower in study clinics using 
Xpert MTB/RIF than in the control clinics using microscopy, 
and the number of people starting TB treatment by 
six months was also not changed. However 
the proportion of people with a confirmed TB 
diagnosis was higher in the clinics using Xpert. 
These results imply that implementation of a new 
diagnostic test with higher sensitivity may not, 
in isolation, improve patient outcomes for drug-
sensitive TB. Improved outcomes may need better 
tests, but also better linkage to TB and HIV care.
Xpert MTB/RIF versus sputum microscopy as the initial 
diagnostic test for tuberculosis: a cluster-randomised 
trial embedded in South African roll-out of Xpert MTB/RIF. 
Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, 
Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, 
Cox HS, Dye C, Grant AD, Fielding KL. Lancet Global Health 2015 
Aug;3(8):e450-7.
TB Fast Track: evaluating empirical TB 
treatment for people with HIV
TB is the most leading cause of death among people with HIV 
worldwide, and limited data suggest that this remains true of 
people starting antiretroviral therapy. However, the diagnosis of 
TB is difficult and may be missed altogether. People with low CD4 
cell counts in particular are less likely to be diagnosed using 
sputum-based tests, because of low mycobacterial concentration 
or inability to produce sputum.
TB Fast Track is a cluster-randomised trial that aims to evaluate 
the effects of targeted empirical TB treatment on early mortality 
in people with HIV accessing antiretroviral therapy in clinics in 
South Africa. The intervention uses a point-of-care technology-
based algorithm to rapidly identify individuals at high risk, and 
ensure they start TB treatment, followed by antiretroviral therapy. 
Mortality in the intervention group will be compared to that 
among adults managed according to standard practice based on 
South African guidelines. 
TB Fast Track is funded by a UK Medical Research Council, 
Department for International Development and Wellcome Trust 
Global Clinical Trials Scheme grant award of £3.2 million.
Principal Investigator: Alison Grant; TB Centre co-investigators: 
Katherine Fielding, Anna Vassall
The quest for new and improved TB vaccines  
The launch of the TBVAC2020 consortium, courtesy of The TB Vaccine Initiative
STAMP trial images courtesy of Zomba 
Central Hospital, Malawi
Field workers testing Xpert MTB/RIF as a first-line TB diagnostic tool, photo courtesy of the XTEND study
TB infected mouse lung tissue, 
courtesy of research student Maria 
Podinovskaia
Peru
Brazil
Malawi
South Africa
Ethiopia
Uganda
India
Pakistan
China
Cambodia
Zambia
Benin
Guinea
Kenya
Senegal
Uzbekistan
Swaziland
Myanmar
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HIV-related TB in Malawi: clinical trials on diagnosis, 
treatment and outcomes
The Malawi-Liverpool-
Wellcome Trust and College 
of Medicine in Blantyre hosts 
many TB Centre investigators 
and projects including 
four major randomised 
controlled trials of diagnostic 
interventions, funded by 
the UK Medical Research 
Council, Department for 
International Development 
and Wellcome Trust Global 
Clinical Trials Scheme, 
as well as the US National 
Institutes of Health and Helse 
Nord.
The site also undertakes comprehensive extended 
monitoring and evaluation of all registering TB patients 
in Blantyre City.  A recently developed online app 
known as “ePAL” – the electronic Participant Locator 
- enables accurate identification of TB hotspots.  The 
centre also has a strong social science theme, for 
example studying masculinity as a barrier to seeking 
TB treatment and medical care.
Contacts: Marriott Nliwasa, Clare Flach, Rebecca 
Harris and Liz Corbett
Health systems and policy research 
Members of the 
TB Centre have 
collaborated on 
two important 
studies in South 
Asia, and are 
engaging in further 
research with 
policy makers. In 
Pakistan we collaborated with the National 
TB Programme on an important cohort study 
which showed that treatment outcomes 
were similar for multi-drug resistant TB 
patients treated using locally procured 
drugs and international quality assured 
drugs. We also conducted a multi-country 
analysis of private sector engagement in TB 
management across South Asia.
Contact: Mishal Khan
Multi-drug resistant TB and interaction with diabetes 
in Peru
In addition to ongoing 
diagnostic, epidemiological 
and genomic studies largely 
focussed on multi-drug 
resistant TB in Peru, Centre 
researchers are working 
with partners at Universidad 
Peruana Cayetano Heredia 
(UPCH) in Lima on the EU-
funded TANDEM consortium 
project. The association 
between TB and diabetes 
mellitus is being investigated 
using established laboratory and community-based 
research platforms here and at partner sites in 
Indonesia, Romania and South Africa. Both the School 
and UPCH are core partners in the global TB genomics 
programme known as CRyPTIC, the Comprehensive 
Resistance Prediction for Tuberculosis International 
Consortium, led by the University of Oxford and funded 
by the Bill & Melinda Gates Foundation.
Contact: David Moore
Malawi Epidemiology and Intervention Research 
Unit The Karonga Prevention Study, now part of the 
Malawi Epidemiology and Intervention Research Unit, 
is using traditional epidemiology and whole genome 
sequencing on long-term population-based data to find 
out how and where TB transmission occurs, whether 
some strains are more transmissible or virulent than 
others, and how TB interacts with HIV. 
Contacts: Judith Glynn and Mia Crampin 
Research Programme on TB control 
In a five year collaboration between the School, Saw Swee Hock School 
of Public Health, University of Singapore, the Cambodia National Institute 
of Public Health and TB Programme, and Phnom Penh University of 
Health Sciences, researchers are conducting a series of linked projects 
in qualitative methods, epidemiology, genomics, transmission dynamics 
modelling and health economics. The overarching goal is to define a variety 
of options to reform Cambodia’s TB Programme and interventions, and to 
assess their likely impact and costs over the next 15 years. 
Contacts: Richard Coker and Mishal Khan
Interlinked Projects in Myanmar and 
Yunnan Province, China 
In Myanmar, TB 
Centre researchers 
are undertaking a 
case control study 
to determine risk 
factors associated 
with multi-drug 
resistant TB. In 
Yunnan, qualitative research is addressing 
questions of access and stigma amongst 
patients with TB and the role of gender 
in seeking health services. We are also 
analysing the costs and cost-effectiveness 
of community-based multi-drug resistant 
TB treatment programmes. These projects 
are funded by USAID, and we are working 
in collaboration with FHI360, Myanmar 
National TB Programme and Yunnan Centre 
for Disease Control.
Contacts: Richard Coker and Mishal Khan
Improving adherence to treatment for drug-sensitive TB
Mobile text messaging and medication monitors have the potential 
to improve adherence to TB treatment and reduce the need for 
directly observed treatment. Researchers from the School and the 
National Center for Tuberculosis Control and Prevention in China 
conducted a cluster-randomised trial in four provinces in China, to 
assess the effectiveness of these interventions. 
Patients either received text message reminders, an electronic 
medication monitor, both, or no reminders for their six month 
treatment period. Patients receiving no reminders missed 30% of their 
medication doses and patients receiving text messages missed 27%. However, patients with 
an electronic medication monitor box – which beeps if not opened at the agreed time – only 
missed 17% of doses, and those who received both text messages and medication monitors 
missed just 14%, clearly demonstrating effectiveness. A second study is now underway, using 
a more robust medication monitor and examining clinical outcomes. These studies are funded 
by the Bill & Melinda Gates Foundation.
Contacts: Katherine Fielding and James Lewis
The immunology of TB in adults and infants
We have several projects around the 
immunology of TB in both adults and 
infants, funded by the UK Medical Research 
Council, The Wellcome Trust and the 
European Union. In adults, we have a 
particular interest in the B cell immune 
response to TB, and also in clinical trials of 
new TB vaccines. In infants, we have two 
projects looking at whether the latent TB 
infection status of pregnant mothers affects 
their children’s response to BCG following 
birth, including a randomised controlled trial 
of delayed BCG, to determine whether BCG 
non-specifically stimulates the infant innate 
immune system to protect against unrelated 
infections. 
Contacts: Stephen Cose, Sarah Prentice 
and Alison Elliott
Africa Centre TB programme
KwaZulu-Natal has very high TB incidence, and the highest 
prevalence of multi-drug resistant TB in South Africa. Here, 
the Africa Centre, in which the School is a key collaborator, is 
developing a multidisciplinary research programme in order to 
understand TB transmission, and develop interventions to interrupt 
it. Initial projects include a TB treatment cohort including multi-drug 
resistant TB, using epidemiological, geospatial and molecular data 
to understand TB transmission networks; and a study to estimate 
the incidence of TB infection among adolescents.
Contacts: Alison Grant and Richard Lessells
HIV-related TB co-infection in Brazil
A two-year clinical trial with individual 
randomisation led by epidemiologists 
from the Oswald Cruz Foundation in 
Recife, Brazil and the School started in 
March 2014. The objective is to estimate 
the incremental cost-effectiveness of 
a protocol for screening and diagnosis 
of TB in HIV patients. The study includes 
screening by clinical algorithm, followed by 
diagnosis with gene Xpert MTB/RIF, sputum smear microscopy and 
chest X-ray.
Contact: Noemia Teixeira-Filha
Clinical trials looking at immunological reactions in leprosy
Work in Ethiopia on leprosy has involved 
clinical trials looking at ciclosporin as a 
treatment for immunological reactions 
in leprosy, assessing reaction severity 
scale and quality of life tools, as well 
as observational studies in patients co-
infected with HIV and leprosy. This work 
has contributed towards an important 
project with the Ministry of Health in Ethiopia mapping leprosy.
Contacts: Saba Lambert and Diana Lockwood
TB programmes in Zambia
Zambart is a major research collaboration 
between the School and the University 
of Zambia. Current Zambart studies 
include a TB vaccine trial with Aeras and 
GlaxoSmithKline, diagnostics studies of 
Quantiferon plus, a TB and meningitis study, 
and a study of the relationship between TB, 
HIV and diabetes, as well as HPTN071/
PopART which looks at TB in the context of 
universal test and treat for HIV. 
Contacts: Helen Ayles 
Selected TB Centre activities around the world
Leprosy projects in India
Patients with leprosy and neuropathic pain report a 
poor quality of life and psychological wellbeing. In a 
project looking at nerve damage characteristics and 
somatosensory profiles of leprosy patients in low-
resource settings, School researchers have identified a 
novel profile of sensory loss to thermal and mechanical 
sense, combined with preservation of vibration sense. 
They have also shown that adding azathioprine to leprosy 
immune-suppression does not improve patient outcomes, 
an important negative result. 
Contacts: Omer Haroun and Diana Lockwood
Treatment trials for drug-sensitive and drug-resistant TB
A recently completed trial in adults with drug-sensitive pulmonary 
TB in five countries in Africa showed that a four-month experimental 
treatment with the drug gatifloxacin was not as effective as the 
standard treatment with ethambutol for six months. These results 
were published in the New England Journal of Medicine in 2014, 
and we are now working with Médecins Sans Frontières on a new 
trial using bedaquiline and pretomanid. 
Contacts: Katherine Fielding, Elizabeth Allen and Dave Moore
Note: The lines and points on the map indicate in which areas these projects are 
based. They are not meant to be geographically accurate.
Photo courtesy of 
Rebecca Kanter
Photo courtesy of Liz 
Corbett
Photo courtesy of 
Noemia Teixeira-Filha
Photo courtesy of WHO/
Rochkind
Photo courtesy of 
Richard Coker
Photo courtesy of Tim 
Quijano /Flickr
Photo courtesy of Saba 
Lambert
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Towards better control of HIV-related TB 
TB Modelling and Analysis Consortium
The TB Modelling and Analysis Consortium (TB MAC) is a 
global community of TB modellers who provide quantitative 
support for TB policy decisions and implementation. By 
promoting collaboration and funding research projects, TB MAC 
has since its inception in 2012 been of great influence in policy 
debates, and developing the global field of TB modelling.
On the global policy level, TB MAC has updated the World 
Health Organization methods used to estimate the amount 
of HIV-related TB globally, and provided input on technical 
discussions that resulted in the decision by the Global Fund to 
Fight AIDS, TB and Malaria not to reduce the proportion of funds 
it allocates to TB. In recent years, TB MAC has also supported 
the development of tools to integrate modelling into country-level 
policy discussions. These have been used in collaborations with 
UNAIDS, the World Health Organization, and the governments of 
Vietnam, Ghana, South Africa.
In response to the post-2015 End TB Strategy, TB MAC has 
led the first multi-model TB comparison exercise to assess the 
feasibility of the new targets of 50% reduction in TB incidence 
and 75% reduction in TB mortality by 2025 for China, India and 
South Africa. This work coordinated the efforts of 11 modelling 
groups, a team of economists and representatives from the 
The ZAMSTAR trial: community TB testing 
and counselling
The Zambia and South Africa tuberculosis and AIDS reduction 
study (ZAMSTAR) was a cluster-randomised trial of two 
interventions to reduce the burden of TB at community-level. 
One was improved community-wide TB testing and the other a 
household-level intervention to provide TB and HIV counselling 
to facilitate prompt diagnosis and treatment. The trial was 
conducted in 24 communities in Zambia and the Western Cape 
province of South Africa, in partnership with the Zambia AIDS 
Related TB (ZAMBART) Project and the Desmond Tutu TB Centre 
at Stellenbosch. 
Around a million people were involved in the trial at a cost of less 
than one US dollar per person per year. 
The study’s main finding, published in the Lancet, showed that 
the household intervention may have reduced prevalence of TB 
in adults, and that children in the communities that received 
household counselling were half as likely to become infected 
with TB. 
“In these communities, TB and HIV 
affect the entire household, so you 
need to involve not only the TB patient 
but his or her entire family. If adults 
are not diagnosed and treated, they 
can infect children” 
Helen Ayles, ZAMSTAR Principal Investigator 
Data from the trial have already been instrumental in shaping 
World Health Organization guidelines, both for screening for 
active TB among people living with HIV and for community TB 
screening.
Ayles H, Muyoyeta M, Du Toit E, Schaap A, Floyd S, Simwinga M, 
Shanaube K, Chishinga N, Bond V, Dunbar R, De Haas P, James A, 
Gey van Pittius NC, Claassens M, Fielding K, Fenty J, Sismanidis C, 
Hayes RJ, Beyers N, Godfrey-Faussett P. Effect of household and 
community interventions on the burden of tuberculosis in southern 
Africa: the ZAMSTAR community-randomised trial. Lancet. 2013 Oct 
5;382(9899):1183-94.
Murray EJ, Bond VA, Marais BJ, Godfrey-Faussett P, Ayles HM, Beyers N. 
High levels of vulnerability and anticipated stigma reduce the impetus for 
tuberculosis diagnosis in Cape Town, South Africa. Health Policy Plan. 
2013 Jul;28(4):410-8.
The Consortium to Respond Effectively to the AIDS/TB 
Epidemic (CREATE) is an international research consortium 
funded by the Bill & Melinda Gates Foundation to assess the 
impact of novel strategies for controlling HIV-related TB. It 
has funded three large cluster-randomised trials including 
the ZAMSTAR and Thibela TB studies, in which TB Centre 
researchers have leading roles.
Thibela TB: mass screening and treatment 
in mining communities
The Thibela TB study was conducted in South African goldmines 
where notification rates of people with TB in 2008 were 3,000 
per 100,000 miners, despite a control programme in the mines 
following international guidelines, and regular radiological 
screening. Since conventional control methods were not working 
in this setting, we investigated a radical method to control 
TB. Thibela TB, which is “Prevent TB” in Sesotho, took the 
approach of screening the whole workforce for TB, treating those 
diagnosed and providing preventive therapy (nine months of 
anti-TB drug isoniazid) for those eligible. This intervention was 
compared with the current standard of care, and we assessed 
the overall impact on TB incidence and prevalence. 
The Thibela TB study has generated 23 publications including 
contributions to a supplement in AIDS in 2010, and we 
continue to analyse data. Safety data and our experiences of 
implementing isoniazid preventive therapy has contributed to the 
roll-out of preventive therapy for people living with HIV. Our main 
findings, published in the New England Journal of Medicine in 
2014, disappointingly  showed the intervention did not improve 
TB control at the population-level in these gold mines. A large 
scale mathematical modelling exercise helped to explain our 
results and suggested that a much more intensive “combination 
prevention” approach will be needed to improve TB control in the 
mines. 
Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-
Faussett P, Hayes RJ, Chaisson RE, Grant AD; Thibela TB Study Team. A 
trial of mass isoniazid preventive therapy for tuberculosis control. New 
Engl J Med. 2014; 370(4):301-10. 
Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, Corbett 
EL, Churchyard GJ, Grant AD, White RG. Tuberculosis control in South 
African gold mines: mathematical modeling of a trial of community-wide 
isoniazid preventive therapy. Am J Epidemiol. 2015 Apr 15;181(8):619-32. 
country National TB Programmes and advocacy communities. 
Results from this work have informed policy discussions, in 
particular in South Africa, where the work has influenced budgets 
and operational research priorities. The modelling is being used 
in South Africa in their first ever combined TB and HIV Investment 
Case.
The consortium is open to anyone who is interested in 
quantitative methods to improve TB policy and practice. It is 
funded by a grant to the School from the Bill & Melinda Gates 
Foundation.
TB centre members: Richard White, Rein Houben, Christina 
Albertsen, Anna Vassall
Houben, R. M., D. W. Dowdy, A. Vassall, T. Cohen, M. P. Nicol, R. M. 
Granich, J. E. Shea, P. Eckhoff, C. Dye, M. E. Kimerling, R. G. White 
and T. M. T.-H. m. participants (2014). “How can mathematical models 
advance tuberculosis control in high HIV prevalence settings?” Int J 
Tuberc Lung Dis 18(5): 509-514.
Zwerling, A., R. G. White, A. Vassall, T. Cohen, D. W. Dowdy and R. 
M. G. J. Houben (2014). “Modeling of Novel Diagnostic Strategies 
for Active Tuberculosis – A Systematic Review: Current Practices and 
Recommendations.” PLoS ONE 9(10): e110558.
Thibela TB project with gold miners in South Africa (see page 6), photo courtesy The Aurum Institute
Field workers at Ndirande clinic, Malawi, courtesy of Liz Corbett
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Interactions between TB and diabetes
Diabetes associated with increased risk of 
TB in the United Kingdom
Researchers at the TB Centre have used UK electronic routine 
health records to study the association between diabetes 
and TB. The project used data taken from general practice 
consultations and records for up to six million patients over more 
than 20 years and produced a cohort of more than a quarter of a 
million patients with diabetes, who were compared with a control 
group and followed up for incident TB disease.
Despite the UK having a very effective primary health care 
system that incentivises high quality care for chronic diseases 
such as diabetes, the increased risk of TB was still evident. 
The study showed that those accessing the least amount of 
diabetes care were at the greatest risk for TB. The findings have 
implications for UK national policy proposing to provide high risk 
groups access to TB screening and treatment in primary care 
settings.
TB Centre members: Louise Pealing, David Moore
Risk of tuberculosis in patients with diabetes: population based cohort 
study using the UK Clinical Practice Research Datalink. Louise Pealing, 
Kevin Wing, Rohini Mathur, David Prieto-Merino, Liam Smeeth, David A J 
Moore. BMC Medicine 06/2015; 13(1):135.
Distance learning TB module
The TB module is part of the School‘s Infectious Diseases MSc distance learning course. It is multidisciplinary, with biology, 
pathology and immunology balanced with considerations of broader social and ethical issues. The study material is delivered in 
digital format, with interactive exercises, figures and animations, and a team of 15 tutors supports learning via virtual learning 
environment discussion forums. Our student body is highly diverse, with approximately 120 students registered each year from 
around 40 countries worldwide. For full details, visit www.lshtm.ac.uk or contact module organiser jackie.cliff@lshtm.ac.uk.
Current PhD students working on TB-related projects
Taught courses and research degrees  
relating to TB
TB and diabetes mellitus in TANDEM
Diabetes increases the risk of TB and seems to impair response 
to TB treatment. The TANDEM Consortium, funded by the 
European Union, is investigating the links between TB and type 
2 diabetes. Through field work in Peru, South Africa, Romania 
and Indonesia, TANDEM will determine the most cost-effective 
approaches to screening for diabetes in TB patients and for TB 
in diabetes patients. Together with partners in the Netherlands, 
Germany and New Zealand, molecular interactions between M. 
tuberculosis infection and diabetes are being elucidated using 
fat cells, macrophages, global gene expression analysis and 
genetic analysis. The TANDEM consortium is funded by a four 
year European Union grant award of 5.9 million euros.
TB Centre members: Hazel Dockrell, Jackie Cliff, Clare Eckold, 
David Moore, Ulla Griffiths, Yoko Laurence
TANDEM: understanding diabetes and tuberculosis. Reinout van Crevel 
and Hazel M. Dockrell; TANDEM Consortium. Lancet Diabetes Endocrinol, 
2014; 2(4):270-2.
Student Project title
Mateusz Hasso Agopsowicz  Epigenetics and immune responses to BCG vaccine 
Shaheda Anwar Impact of helminth infection on antimycobacterial Immune responses in UK migrants
Katherine Horton Understanding and assessing the potential impact and cost-effectiveness of targeting men in 
 systematic screening for tuberculosis
Sean M. Cavany Optimising contact tracing for tuberculosis in England
Sophie Rhodes Developing a mathematical modelling framework to predict the best dose in humans for TB 
 vaccines using animal data
Rebecca Harris Informing clinical development of novel TB vaccines through mathematical modelling and 
 development of novel epidemiological tools.
Natascha Meunier Characterising bovine tuberculosis in and around the Queen Elizabeth National Park, Uganda
Clare Eckold Host blood gene expression changes through tuberculosis treatment: effect of HIV or type 2  
 diabetes co-morbidity
Sarah Lou Bailey Understanding the threat of diabetes mellitus to tuberculosis control in sub-Saharan Africa: the 
 impact of HIV and diabetes control
Noemia Teixeira-Filha The treatment of HIV/AIDS in Brazil: economic evaluation of strategies for screening and diagnosis 
 of tuberculosis in people living with HIV/AIDS and the use of antiretroviral therapies as a way to 
 reduce morbidity and mortality of tuberculosis in this population
Yoko Laurence Economic evaluation of screening and treatment strategies for concurrent TB and DM in Indonesia, 
 Peru and Romania
Lisa Stockdale Measuring the impact of vaccination on TB drug efficacy
Satria A. Prabowo Investigation of therapeutic vaccination strategy for tuberculosis in an ex-vivo mycobacterial growth 
 inhibition assay
Charlotte Sarfas Influence of age on the T-cell immune response in BCG vaccinated Rhesus macaques 
Ivanice Freire Incidence risk of progression to tuberculosis in migrants with fibrotic lesions suggestive of post-TB  
 scarring
Patrick Nguipdop-Djomo Re-emergence of tuberculosis in Western high-income low incidence countries: Levels of BCG 
 vaccines derived protection, and the role of social deprivation
Joilda Nery Silva Effect of a cash transfer programme on tuberculosis incidence, and treatment success in Brazil 
William Rudgard Estimate the potential mitigation effect of social protection on TB catastrophic costs
Palwasha Khan Investigating Mycobacterium tuberculosis transmission in rural Malawi
Ankur Gupta-Wright Hospitalised patients with HIV-associated TB diagnosed by rapid urine-based diagnostic assays: an 
 investigation of factors associated with mortality
Yasmeen Hanifa A study of the frequency and underlying causes for “TB symptoms” in patients attending for HIV 
 care in South Africa
Aaron Karat Prevalence of TB and other treatable diseases at autopsy in South Africa
Patrice Akusa Mawa The impact of maternal infection with Mycobacterium tuberculosis on the infant response to BCG 
 immunisation
Sarah Prentice Does neonatal BCG vaccination provide protection against heterologous pathogens by stimulating 
 the innate immune system?
Amera Khan Determining the feasibility and acceptability of implementing a latent TB infection testing and 
 treatment program at overseas panel sites for US bound immigrants
Jody Phelan Tuberculosis host and pathogen genomics
Sedona Sweeny Improving methods to evaluate the poverty impact of disease
Debora Pedrazzoli Impact of socioeconomic determinants on TB control 
Marek Lalli Modelling the dynamics and impact of targeted interventions for high-risk groups for National 
 Strategic Plans against tuberculosis: development and application of a modelling tool for in-country  
 decision making
TANDEM project worker screening for diabetes in TB 
patients in Lima, Peru, courtesy of Cesar Ugarte
